个人简历

任职广西科协副主席，省部共建药用资源化学与药物分子工程国家重点实验室主任，广西师范大学博士生导师，兼任南开大学、南京大学无机化学博士生导师和中南大学应用化学博士生导师。研究成果主要发表在Nature Communications、Angew Chem Int Ed、Molecular Pharmaceutics、Journal of Medicinal Chemistry、Eur Chem J、Chem Comm和《中国科学》等国内外权威期刊300余篇, 并被国内外学者在SCI期刊引用约3000次；多次获得广西科技进步一等奖和广西自然科学一等奖；授权20项国家发明专利

研究领域

"""""新型抗肿瘤金属药物和载药体系\r
1）细胞迁移机制\r
2）基于DNA和蛋白质设计新型抗肿瘤金属药物\r
3） 蛋白质和纳米载药体系"

近期论文

Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In Vivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nature Communications. 2016, 7:11692. (综合性顶级期刊)\r
\r
YL Ma, JP Yue, Y Zhang, CZ Shi, M Odenwald, WG Liang, Q Wei, A Goel, XW Gou, J Zhang, SY Chen, WJ Tang, JR Turner, F Yang*,H Liang*, HL Qin*, XY Wu*. ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications. 2017,8: 15375.\r
\r
Chen ZF*, Qin QP, Qin JL, Liu YC, Huang KB, Li YL, Meng T, Zhang GH, Peng Y, Luo XJ, Liang H*. Stabilization of G-quadruplex DNA, inhibition of telomerase activity, and tumor cell apoptosis by organoplatinum(II) complexes with oxoisoaporphine. J Med Chem. 2015; 58: 2159-2179. (药物化学顶级期刊）\r
\r
Chen ZF*, Qin QP, Qin JL, Zhou J, Li YL, Li N, Liu YC, Liang H*. Water-soluble ruthenium(II) complexes with chiral 4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivo anticancer activity by stabilization of G-Quadruplex DNA, inhibition of telomerase activity, and induction of tumor cell apoptosis. J Med Chem. 2015; 58: 4771-4789.\r
\r
ou Y, Qi JX, Zhang Y, Jiang M, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and human serum albumin carrier IIA subdomain. Molecular Pharmaceutics. 2015, 12: 3597-3609. (药剂学顶级期刊)\r
\r
Y Gou, Y Zhang, ZL Zhang, J Wang, ZP Zhou, F Yang*, H Liang*. Design of an anticancer copper(II) pro-drug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics. 2017, 14: 1861-1873.\r
\r
Qi JX, Zhang Y, Gou Y, Zhang ZL, Zhou ZP, Wu XY, Yang F*,Liang H*. Developing an anti-cancer copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA sub-domain. Molecular Pharmaceutics. 2016, 13: 1501−1507.\r
\r
Qi JX, Gou Y, Zhang Y, XY Wu, Yang F*,H Liang*. HSA-based multi-drug delivery systems for combination therapy of three anticancer agents. Molecular Pharmaceutics. 2016, 13: 3098-105.\r
\r
Yang F, Yue J, Ma L, Ma Z, Li M, Wu X, Liang H*. Interactive associations of drug-drug and drug-drug-drug with IIA sub-domain of human serum albumin. Molecular Pharmaceutics. 2012, 9: 3259-65.\r
\r
Jiang BP, Zhou B, Shen XC*, Yu YX, Ji SC, Wen CC, Liang H*. Selective Probing of Gaseous Ammonia Using Red-Emitting Carbon Dots Based on an Interfacial Response Mechanism. Eur Chem J. 2015, 21:18993-9.